Tactile Systems Technology, Inc. Q2 2026 earnings show 9% revenue growth to $85.7M, driven by strong lymphedema sales despite challenges in airway clearance. Net income up 142%.
Tactile Systems Technology, Inc. reported Q2 2026 revenue of $85.7 million, up 9% year-over-year and exceeding the $83.5 million consensus estimate. The growth was significantly driven by the lymphedema segment, which saw strong patient demand despite ongoing challenges in the airway clearance channel due to inventory management dynamics.
Key Takeaways
- Total revenue increased by $6.8 million, or 9%, year-over-year to $85.7 million, surpassing expectations.
- Lymphedema product sales rose 12% to $73.6 million, driven by strong execution and improved referral trends.
- Airway clearance revenue fell 7% to $12.1 million, impacted by temporary inventory management dynamics linked to the launch of the next-generation Aflovest system.
- Gross margin improved to 76.3% from 74.5% year-over-year, reflecting lower manufacturing costs and favorable revenue mix.
- Net income rose 142% to $7.8 million, or $0.34 per diluted share, compared to $3.2 million, or $0.14 per diluted share, in Q2 2025.
Lymphedema Business Drives Revenue Growth
The lymphedema segment was the standout performer, with product sales increasing by 12% to $73.6 million. Management highlighted robust patient demand and improved referral trends, attributing this growth to successful execution across commercial channels. The FlexiTouch product line, in particular, benefitted from enhanced adoption driven by recent Medicare policy changes.
“We continue to see really strong execution across our commercial organization which is both healthy referral trends and improved territory productivity,” said Elaine Carr, CFO.
The company is also optimistic about its recent distribution agreement with Elastomed, aimed at expanding its product offerings in the veteran market. Although no immediate revenue contribution is expected from Myosleave, management views it as a long-term growth contributor.
Airway Clearance Faces Inventory Management Challenges
Airway clearance revenue, which includes the Aflovest system, saw a decline of 7% to $12.1 million due to temporary inventory management issues among key distribution partners. During the launch of the next-generation Aflovest system, some distributors were found to have excess inventory, leading to moderated purchasing activity.
Management expects this trend to improve, with normalized ordering patterns anticipated to return in Q4 2026 as distributors work through existing stock levels.
“We feel confident that we have good visibility now to what the current inventory is,” noted Sherry Smith, CEO, indicating a clear path to recovery for this segment.
Guidance Revised Amid Temporary Dynamics
For the full year 2026, Tactile Systems updated its revenue guidance to a range of $360 to $366 million, representing year-over-year growth of approximately 9% to 11%. The lymphedema segment is expected to continue low double-digit growth, while airway clearance revenue is projected to be flat year-over-year due to the ongoing inventory dynamics.
Management also expects GAAP gross margins to maintain between 76% and 76.5% for the year, with operating expenses anticipated to grow by 10% to 12% as strategic investments in sales and technology are fully realized.
Analyst Q&A Reveals Market Dynamics
During the Q&A session, analysts pressed management on the dynamics affecting the lymphedema business, particularly regarding how prior authorization processes might be influencing order patterns. Management confirmed that while the prior authorization requirements initially caused some order delays, they are now starting to normalize as the team gains experience with the new requirements.
Ryan Zimmerman from US Bancorp BTIG inquired about the impact of the Aflovest product launch on sales patterns. Management emphasized that the current challenges are temporary and specific to a few large distributors, which they are actively addressing.
Frequently Asked Questions
Did Tactile Systems Technology, Inc. beat earnings estimates in Q2 2026?
Yes, Tactile Systems Technology reported earnings of $0.34 per diluted share, beating the consensus estimate of $0.28 by $0.06.
What drove the revenue growth for Tactile Systems in Q2 2026?
The company's revenue grew 9% year-over-year, primarily driven by a 12% increase in lymphedema product sales, thanks to strong patient demand and improved commercial execution.
How is Tactile Systems addressing the challenges in its airway clearance segment?
Management indicated that inventory management dynamics among key distributors impacted airway clearance revenue, but they expect ordering patterns to normalize in Q4 2026 as existing inventory levels are adjusted.
What is Tactile Systems' updated guidance for 2026?
The company now expects total revenue in the range of $360 to $366 million for 2026, reflecting continued strength in the lymphedema business and flat growth in airway clearance revenue.
What are Tactile Systems' gross margin expectations for the year?
Tactile Systems expects its GAAP gross margins to remain between 76% and 76.5% for the full year of 2026.
In summary, while Tactile Systems navigates short-term challenges in its airway clearance segment, the underlying strength in the lymphedema business positions it well for sustained growth moving forward.
This analysis is based on public earnings call materials and is not investment advice.
